Acinetobacter Baumannii News and Research RSS Feed - Acinetobacter Baumannii News and Research

Naturally occurring clay exhibits potent antibacterial activity against ESKAPE pathogens

Naturally occurring clay exhibits potent antibacterial activity against ESKAPE pathogens

Naturally occurring clay from British Columbia, Canada -- long used by the region's Heiltsuk First Nation for its healing potential -- exhibits potent antibacterial activity against multidrug-resistant pathogens, according to new research from the University of British Columbia. [More]
Carbapenem-resistant Enterobacteriaceae: an interview with Dr. Michael Dudley

Carbapenem-resistant Enterobacteriaceae: an interview with Dr. Michael Dudley

Enterobacteriaceae refer to the family of bacteria such as E. coli and Klebsiella that are bacterial pathogens most frequently associated with hospital-acquired infections [More]
Antivirulence antibiotics could evade resistance longer than traditional antibiotics

Antivirulence antibiotics could evade resistance longer than traditional antibiotics

We've all seen the headlines. "Man found to be shedding virulent strain of polio"; "Virulent flu strain in Europe hits the economy"; "Most virulent strain of E. coli ever seen contains DNA sequences from plague bacteria." [More]
New Locilex microbiology data presented at ICAAC/ICC 2015 scientific conference

New Locilex microbiology data presented at ICAAC/ICC 2015 scientific conference

Dipexium Pharmaceuticals, Inc., a late-stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.8%), and research collaborators, JMI Laboratories, announced that new Locilex microbiology data were presented at the American Society for Microbiology's Interscience Conference of Antimicrobial Agents and Chemotherapy and International Society of Chemotherapy's International Congress of Chemotherapy and Infection (ICAAC/ICC 2015) scientific conference in San Diego, California, September 17-21, 2015. [More]
Combination of TXA709 and cefdinir demonstrates synergistic antibacterial activity against MRSA

Combination of TXA709 and cefdinir demonstrates synergistic antibacterial activity against MRSA

TAXIS Pharmaceuticals, a drug-discovery company focused on developing a new class of antibiotic agents to treat life-threatening, multidrug-resistant bacterial infections, announced the presentation of results demonstrating the synergistic antibacterial activity of its lead clinical candidate, TXA709, when combined with cefdinir, a third-generation cephalosporin antibiotic. [More]
Highly diluted acetic acid in vinegar can kill bacteria, prevent infection in burn wounds

Highly diluted acetic acid in vinegar can kill bacteria, prevent infection in burn wounds

Highly diluted acetic acid, an active ingredient of household vinegar, has been shown to be an effective alternative agent to prevent infection and kill bacteria found in burn wounds. [More]
Aridis' AR-301 granted FDA Fast Track Designation for treatment of pneumonia caused by S. aureus

Aridis' AR-301 granted FDA Fast Track Designation for treatment of pneumonia caused by S. aureus

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the U.S. Food and Drug Administration granted Fast Track Designation to AR-301, the Company's fully human anti-Staphylococcal alpha-toxin IgG1 monoclonal antibody (mAb). [More]
Multidrug-resistant bacteria can naturally relinquish its ability to resist antibiotics

Multidrug-resistant bacteria can naturally relinquish its ability to resist antibiotics

Infections with one of the most troublesome and least understood antibiotic-resistant "superbugs" are increasing at alarming rates, particularly in health-care settings. [More]
Aridis expands, accelerates current AR-301 Phase 2a study for treatment of acute pneumonia in the U.S.

Aridis expands, accelerates current AR-301 Phase 2a study for treatment of acute pneumonia in the U.S.

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND) application for AR-301, also referred to as Salvecin, the company's fully human anti-Staphylococcal α-toxin IgG1 monoclonal antibody being developed for the treatment of hospital-acquired and ventilator-associated pneumonia (HAP and VAP) caused by Staphylococcus aureus, including multi-drug resistant 'MRSA' strains. [More]
Aridis' Aerucin gets FDA Fast Track Designation for treatment of hospital-acquired and ventilator-associated pneumonia

Aridis' Aerucin gets FDA Fast Track Designation for treatment of hospital-acquired and ventilator-associated pneumonia

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, announced today that the U.S. Food and Drug Administration granted Fast Track Designation to its fully human monoclonal antibody Aerucin for the treatment of hospital-acquired and ventilator-associated pneumonia caused by Pseudomonas aeruginosa. [More]
Common antibiotic azithromycin effectively kills many multidrug-resistant bacteria

Common antibiotic azithromycin effectively kills many multidrug-resistant bacteria

Contrary to current medical dogma, researchers at University of California, San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences report that the common antibiotic azithromycin kills many multidrug-resistant bacteria very effectively — when tested under conditions that closely resemble the human body and its natural antimicrobial factors. [More]
TAXIS Pharmaceuticals' TXA709 compound shows promise in combating antibiotic resistance

TAXIS Pharmaceuticals' TXA709 compound shows promise in combating antibiotic resistance

TAXIS Pharmaceuticals, a drug-discovery company focused on developing a new class of antibiotic agents to treat life-threatening, multidrug-resistant bacterial infections, today announced the presentation of data demonstrating the promise of its lead clinical candidate, TXA709, in combating antibiotic resistance. [More]
NIAID funds nine research projects to advance rapid diagnostics tests for drug-resistant bacteria

NIAID funds nine research projects to advance rapid diagnostics tests for drug-resistant bacteria

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded more than $11 million in first-year funding for nine research projects supporting enhanced diagnostics to rapidly detect antimicrobial-resistant bacteria. [More]

Aridis Pharmaceuticals begins Aerucin Phase 1 clinical study for treatment of acute pneumonia

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, announced today the initiation of a Phase 1 clinical study of Aerucin, the Company's fully human IgG1 monoclonal antibody (mAb) against Pseudomonas aeruginosa bacteria, which is being developed as an adjunctive treatment for acute pneumonia. [More]
New NIH grant to support development of rapid method for diagnosing mucormycosis

New NIH grant to support development of rapid method for diagnosing mucormycosis

Speed is essential in treating deadly mucormycosis fungal infections, but a quick diagnosis is difficult because no routine blood test exists. [More]
Antibiotic stewardship programs reduce hospital readmissions due to infection

Antibiotic stewardship programs reduce hospital readmissions due to infection

Antibiotic stewardship programs, which promote the appropriate use of antibiotics in hospitals and other healthcare centers, not only lead to reduction in antibiotic use with reduced adverse events, but also lead to significant savings. [More]
New research unit to uncover multi-drug resistant bacteria in hospitals

New research unit to uncover multi-drug resistant bacteria in hospitals

Multi-drug resistant bacteria have increased dramatically in hospitals in recent years and present immense challenges to staff and patients, often with fatal results. [More]

New rapid diagnostic test for multi-resistance to broad-spectrum antibiotics

A rapid diagnostic test for multi-resistance to broad-spectrum antibiotics has just been developed at the University of Fribourg. Prof Patrice Nordmann and Dr Laurent Poirel of the Medical and Molecular Microbiology Unit have been collaborating with Unit 914 of the National Institute of Health and Medical Research (INSERM) in Paris, of which Patrice Nordmann is also Director. [More]
Scientists turn to old class of antibiotics to fight superbugs resistant to modern medicine

Scientists turn to old class of antibiotics to fight superbugs resistant to modern medicine

Scientists at the University at Buffalo are turning to an old class of antibiotics to fight new superbugs resistant to modern medicine. [More]
Cepheid releases molecular test for detection of carbapenemase-producing Gram-negative bacteria

Cepheid releases molecular test for detection of carbapenemase-producing Gram-negative bacteria

Cepheid today announced the release of Xpert® Carba-R, an on-demand molecular test for rapid and accurate detection of carbapenemase-producing Gram-negative bacteria, to be marketed as a CE IVD product under the European Directive on In Vitro Diagnostic Medical Devices. [More]
Advertisement
Advertisement